Skip to content

Multi-center clinical observation and popularization and application of Piwei Peiyuan recipe in the treatment of chronic atrophic gastritis

Multi-center clinical observation and popularization and application of Piwei Peiyuan recipe in the treatment of chronic atrophic gastritis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068458
Enrollment
Unknown
Registered
2023-02-20
Start date
2023-03-01
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic atrophic gastritis

Interventions

treatment group:Piwei Peiyuan granules, Weifuchun simulant
control group:Weifuchun Tablets, Spleen Wei Peiyuan Fang Granules Mimics

Sponsors

Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-70 years old, gender is not limited; 2. Conform to CAG diagnostic criteria, and Helicobacter pylori test is negative (at least one of C13 or C14 breath test is required); 3. Traditional Chinese medicine syndrome differentiation is spleen-stomach weakness syndrome; 4. Voluntary to participate in this project Clinical trials, informed consent and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Complicated with peptic ulcer, pathologically diagnosed as high-grade intraepithelial neoplasia or suspected malignant transformation; 2. Those with severe digestive system disease or history of abdominal surgery; 3. Pregnant and lactating women; 4. Combined with severe heart, lung, Hematopoietic system, malignant tumor and other primary diseases, severe diabetes, chronic liver and kidney dysfunction; 5. Platelets lower than 1.5 times the lower limit of normal; 6. Disabled patients prescribed by law; 7. Long-term use of NSAID drugs, history of alcoholism; 8. Allergic constitution or history of allergy to various drugs; 9. Those who participated in clinical trials of other drugs within the past 4 weeks, or those who have used preparations such as Fuchun and folic acid within the past 2 weeks; 10. Those who are likely to be lost to follow-up.

Design outcomes

Primary

MeasureTime frame
pathological diagnosis;The pathological integral;Results of gastroscopy;TCM syndrome Integral;life quality score;Anxiety indicators;

Countries

China

Contacts

Public ContactLi Xuejun

Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

lixuejun0308@126.com+86 551 6266 8504

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026